September 13, 2019 / 9:39 AM / a month ago

BRIEF-Halozyme Says Global Phase III FeDeriCa Study Conducted By Genentech Met Its Primary Endpoint

Sept 13 (Reuters) - Halozyme Therapeutics Inc:

* POSITIVE RESULTS ANNOUNCED FROM PHASE 3 TRIAL EVALUATING FIXED-DOSE SUBCUTANEOUS COMBINATION OF PERJETA® AND HERCEPTIN® USING HALOZYME'S ENHANZE® DRUG DELIVERY TECHNOLOGY

* GLOBAL PHASE III FEDERICA STUDY CONDUCTED BY GENENTECH, A MEMBER OF ROCHE GROUP, MET ITS PRIMARY ENDPOINT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below